Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633112 | 0.89 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL3634207 | 0.87 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL76307 | 0.83 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL14012457 | 0.83 | QPCTL (1.00) | QPCTQPCTL | |
| SCHEMBL3633424 | 0.83 | QPCTL (1.00) | QPCTQPCTL | |
| SCHEMBL5064458 | 0.83 | QPCTL (1.00) | QPCTQPCTL | |
| SCHEMBL8125693 | 0.81 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL3627585 | 0.79 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL8135475 | 0.78 | QPCT (0.64) | QPCTQPCTL | |
| SCHEMBL12989362 | 0.76 | QPCT (0.63) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146968-B1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-09-23 | — | — | EP | claimed |
| EP-2146968-A1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-27 | — | — | EP | claimed |
| WO-2008128986-A1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | claimed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | claimed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| EP-2146968-B1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2146968-A1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008128986-A1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | MAPT, SLC10A1, REN | QPCT 3498/4885QPCTL 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.